Sensus Healthcare, Inc. Annual Report - A Deep Dive into 2025 Performance and Future Strategy

Understanding Sensus Healthcare, Inc.'s financial health and strategic direction is crucial for investors. This summary provides a clear overview of their performance for the year ending December 31, 2025, based on their latest annual report.

2025 Highlights at a Glance:

• Revenue Growth: Sensus achieved $48.5 million in total revenue, marking a 15% increase from $42.2 million in 2024.
• Profitability: The company reported a net income of $3.1 million, or $0.19 per diluted share, a significant improvement from a net loss of $0.5 million in 2024.
• Installed Base Expansion: Sensus grew its global installed base to 955 SRT devices, adding 110 new units in 2025, primarily driven by U.S. demand.
• Strategic Shift: The "Fair Deal Agreement" model, successfully launched in 2024, contributed 12% of total revenue in 2025. Sensus also prepared for the 2026 launch of Sensus Healthcare Financial Services to boost accessibility.
• Strong Margins: The company maintained a robust gross profit margin of 68%.

Business Overview: What Sensus Healthcare Does

Sensus Healthcare is a medical device company specializing in non-invasive treatments for non-melanoma skin cancer and keloid scars. Their core technology, Superficial Radiation Therapy (SRT), uses low-energy X-rays, offering a non-surgical alternative particularly appealing for cosmetically sensitive areas. As of December 31, 2025, Sensus had 955 SRT devices installed across 21 countries, with approximately 85% located in the United States.

Main Products & Services

Sensus offers a tiered product line and comprehensive service solutions:

• SRT-100™: This foundational system provides a gentle, non-surgical option for skin cancers and keloids, known for its ease of use and reliability.
• SRT-100 Vision™: An advanced system, it incorporates high-frequency ultrasound imaging for precise treatment planning and real-time tracking, enhancing treatment accuracy and patient outcomes.
• SRT-100+™: This model expands on the SRT-100 with an increased energy range for customized treatments, remote diagnostic capabilities, and an improved X-ray tube for enhanced performance and longevity.

Beyond device sales, Sensus provides:

• Sentinel Service Program: This critical recurring revenue stream offers extended warranties, parts, labor, and annual maintenance. It generated $7.2 million in revenue in 2025, representing 15% of total revenue, and boasts a 90% renewal rate among eligible customers. The program also includes comprehensive support from room setup to staff training.
• Fair Deal Agreement (Launched February 2024): This innovative "turn-key" solution allows dermatology clinics to offer SRT treatments without significant upfront capital expenditure. Sensus provides the SRT system, a dedicated technician, and oversight from radiation oncologists and physicists. In return, Sensus receives a percentage of the insurance reimbursements collected by the clinic for SRT treatments. This model contributed $5.8 million in revenue in 2025 from 25 active agreements, demonstrating its potential for stable, recurring income.
• Sensus Healthcare Financial Services (Launching February 2026): To further reduce adoption barriers, Sensus partners with third-party banks to offer flexible financing options, including outright purchases and various leasing plans. This initiative projects an additional 10-15% growth in device placements in 2026.

Financial Performance (Year Ended December 31, 2025)

Sensus Healthcare demonstrated solid financial growth in 2025:

• Total Revenue: Revenue increased to $48.5 million from $42.2 million in 2024, driven by both device sales and growing service revenue.
• Gross Profit: Gross profit rose to $33.0 million (68% gross margin) compared to $28.7 million (68% gross margin) in 2024, indicating consistent profitability.
• Operating Expenses: Operating expenses totaled $29.0 million, up from $27.5 million in 2024, reflecting increased investment in sales, marketing, and R&D for new product development.
• Net Income: The company achieved a positive $3.1 million net income, a significant turnaround from a net loss of $0.5 million in 2024. This translates to $0.19 per diluted share.
• Cash Flow from Operations: Sensus generated $4.5 million in positive cash flow, strengthening its liquidity.

Management's Discussion and Analysis (MD&A) Highlights

Management highlighted the successful execution of strategic initiatives as key drivers for the improved financial performance in 2025. Strong demand for SRT devices in the U.S. market and the increasing contribution from the Fair Deal Agreement model primarily drove the 15% revenue growth. This model demonstrated its potential for recurring revenue streams. Increased sales volume, consistent gross margins, and effective operating expense management relative to revenue growth directly resulted in the significant shift from a net loss in 2024 to a net income of $3.1 million in 2025.

Strategic investments in sales and marketing to expand market reach and support the Fair Deal model, as well as continued R&D efforts to enhance product offerings, primarily drove the increase in operating expenses. Management emphasizes these investments are crucial for long-term growth and market leadership. Positive cash flow from operations reflects the company's ability to generate cash internally, supporting working capital needs and future investments without significant reliance on external financing.

Management anticipates the 2026 launch of Sensus Healthcare Financial Services will further accelerate device placements by addressing capital expenditure barriers for potential customers, sustaining revenue growth. The company continues to monitor the competitive landscape, reimbursement policies, and supply chain dynamics—critical factors influencing future performance.

Financial Health

As of December 31, 2025, Sensus held $12.8 million in cash and cash equivalents, demonstrating a strong liquid position. The company's long-term debt stood at $5.0 million, indicating a manageable debt load relative to cash reserves and operational cash flow. Generating $4.5 million in positive cash flow from operations further underscores the company's financial stability and ability to fund growth initiatives and meet obligations. This healthy balance sheet and robust cash generation provide Sensus the flexibility to pursue strategic objectives and navigate potential market fluctuations.

Future Outlook and Strategic Focus

Sensus strategically positions itself for continued growth by:

• Expanding the Fair Deal Model: The company aims to increase active Fair Deal agreements by 30% in 2026, targeting higher recurring revenue and deeper market penetration without requiring upfront capital from clinics.
• Leveraging Financial Services: Sensus expects new financing options, launching in February 2026, to accelerate device placements and market penetration, particularly among smaller clinics and those with budget constraints. This initiative projects an additional 10-15% growth in device placements in 2026.
• Innovation: The company continues R&D efforts to enhance existing SRT technology and explore new applications, with a new software update for the Vision system planned for late 2026 to improve precision and user experience.
• International Expansion: While the U.S. remains primary, Sensus explores opportunities in select European and Asian markets, focusing on regions with favorable reimbursement environments and a high incidence of non-melanoma skin cancer.

Competitive Position

Sensus Healthcare operates in a competitive medical device market for non-melanoma skin cancer and keloid treatment. Its proprietary Superficial Radiation Therapy (SRT) technology provides a primary competitive advantage, offering a non-surgical, non-invasive, and cosmetically appealing alternative to traditional treatments like Mohs surgery, cryotherapy, and excisional surgery. The SRT-100 Vision™ system further differentiates Sensus by integrating high-frequency ultrasound imaging, which provides real-time treatment planning and visualization, enhancing precision and patient outcomes.

The company's innovative business models, such as the Fair Deal Agreement, also provide a competitive edge. They lower the barrier to entry for clinics, allowing them to offer SRT treatments without significant upfront capital investment. This model, along with the upcoming Sensus Healthcare Financial Services, positions Sensus to capture market share from clinics that might otherwise hesitate to adopt new technology due to cost. While Sensus faces competition from established players offering various treatment modalities (surgical, laser, other radiation therapies), it aims to distinguish itself through its focus on patient comfort, cosmetic results, and flexible partnership models.

Key Risks to Consider

While Sensus shows promise, investors should be aware of specific risks:

• Reimbursement Uncertainty: Changes in insurance reimbursement policies or rates for SRT treatments, particularly from Medicare and private payers, could directly impact clinic profitability and, consequently, Sensus's revenue from device sales and Fair Deal agreements.
• Customer Concentration: A single large U.S. customer generated approximately 18% of Sensus's 2025 revenue. Additionally, sales in China, while growing, face geopolitical and regulatory uncertainties. Adverse developments with these key customers or regions could materially affect financial performance.
• Intense Competition: The medical device market for skin cancer and keloid treatment is competitive, with established players and emerging technologies. Sensus faces competition from surgical, cryotherapy, laser, and other radiation therapy solutions.
• Regulatory Compliance: As a medical device company, Sensus operates under stringent FDA and international regulations. Failure to comply, or significant changes in regulatory requirements, could lead to costly delays, product recalls, or market withdrawal.
• Supply Chain and Inflation: Ongoing global supply chain disruptions and inflationary pressures could increase manufacturing costs, impacting gross margins if Sensus does not effectively manage them through pricing adjustments or operational efficiencies.
• Intellectual Property Protection: Sensus relies heavily on its patents and proprietary technology. Inability to protect its intellectual property, or allegations of infringing on others' patents, could harm its competitive position and financial health.

Market Context

As of December 31, 2025, the company's market capitalization (excluding insider-held shares) was approximately $70.9 million. The company had 16.5 million shares of common stock outstanding as of February 24, 2026. This positions Sensus as a small-cap company with growth potential.